Phosphatase

Phosphatases are enzyme that remove a phosphate group from a protein. Protein tyrosine phosphatases (PTPs) comprise a diverse family of transmembrane and cytoplasmic enzymes. PTPs play an important role in regulating the proliferative activity of cells and the integrity of cell-cell and cell-matrix contacts. Protein tyrosine phosphatase 1B (PTP1B) is a non-receptor PTP frequently associated with the endoplasmic reticulum and vesicles subjacent to the plasma membrane. PTP1B as a key negative regulator of leptin receptor pathways has been an attractive therapeutic target for the treatment of type 2 diabetes mellitus and obesity. Four major serine/threonine-specific protein phosphatase catalytic subunits are present in the cytoplasm of animal cells. Three of these enzymes, PP1, PP2A, and PP2B, are members of the same gene family, while PP2C appears to be distinct.The alkaline phosphatases comprise a heterogeneous group of enzymes that are widely distributed in mammalian cells. Acid phosphatase enzymes catalyze the hydrolysis of phosphate monoesters following the general equation.

(-)-p-Bromotetramisole oxalate

(L-p-Bromotetramisole oxalate; 6-Bromolevamisole oxalate) Cat. No.: HY-19695

(-)-p-Bromotetramisole Oxalate is a potent and non-specific alkaline phosphatase inhibitor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

(E,E)-RAMB4

Cat. No.: HY-128978

(E,E)-RAMB4 is a potent and selective **potent protein tyrosine phosphatase-1B (PTP1B)** inhibitor extracted from patent CN103626692A, example 1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-BCI

(NSC 150117) Cat. No.: HY-126390

(E/Z)-BCI (NSC 150117) is a **dual-specificity phosphatase 6 (DUSP6)** inhibitor with anti-inflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-RK-682

Cat. No.: HY-135564B

(Rac)-RK-682, a racemate of RK-682, is a **protein tyrosine phosphatases (PTPases)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Naphthyl phosphate potassium salt

Cat. No.: HY-113821

1-Naphthyl phosphate potassium salt is a non-specific **phosphatase** inhibitor. 1-Naphthyl phosphate potassium salt decreases the splice-correcting effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-Bromo-4'-hydroxyacetophenone

Cat. No.: HY-W002314

2-Bromo-4'-hydroxyacetophenone a **PTP1B** inhibitor, with a K_i of 42 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg

3,5-Difluoro-L-tyrosine

Cat. No.: HY-136595

3,5-Difluoro-L-tyrosine is a functional, tyrosinase-resistant mimetic of tyrosine. 3,5-Difluoro-L-tyrosine can be used to analyze the substrate specificity of protein tyrosine phosphatases (PTPs).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

3α-Aminocholestane

Cat. No.: HY-19776

3α-Aminocholestane is a selective **SH2 domain-containing inositol-5'-phosphatase 1** (**SHIP1**) inhibitor with an IC_{50} of ~2.5 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

5-FAM-Alkyne

Cat. No.: HY-130913

5-FAM-Alkyne is a high selective and sensitive fluorescent biosensor for alkaline phosphatase (ALP).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6-Hydroxybenzbromarone

Cat. No.: HY-135774

6-Hydroxybenzbromarone is the major **metabolite** of Benzbromarone with a longer half-life and greater pharmacological potency than the parent compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

7-BIA

Cat. No.: HY-115496

7-BIA is a **receptor-type protein tyrosine phosphatase D (PTPRD)** inhibitor with an IC_{50} of ~1-3 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ABBV-CLS-484

Cat. No.: HY-145923

ABBV-CLS-484 is a potent **PTPN1** or **PTPN2** inhibitor with a sub-nanomolar activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Aloe-emodin-8-O-β-D-glucopyranoside

Cat. No.: HY-N2451

Aloe-emodin-8-O-β-D-glucopyranoside, a compound isolated from Saussrurea lappa, is a moderate inhibitor of **human protein tyrosine phosphatase 1B (hPTP1B)** with an IC_{50} of 26.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AQX-016A

Cat. No.: HY-115620

AQX-016A is an orally active and potent **SHIP1** agonist. AQX-016A can activate recombinant **SHIP1** enzyme in vitro and stimulate **SHIP1** activity. AQX-016A also can inhibit the **PI3K** pathway and TNFa production, can be useful for various inflammatory diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AQX-435

Cat. No.: HY-136268

AQX-435 is a potent **SHIP1 phosphatase** activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARL67156 trisodium salt

Cat. No.: HY-103265

ARL67156 trisodium salt is an inhibitor of **ecto-ATPase**. ARL 67156 trisodium salt is a weak competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12μM, respectively.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

ARL67156 trisodium salt hydrate

Cat. No.: HY-103265B

ARL67156 trisodium salt hydrate is an inhibitor of **ecto-ATPase**. ARL67156 trisodium salt hydrate is a weak competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS1949490

Cat. No.: HY-18686

AS1949490 is a potent and selective **SHIP-2 (SH2 domain-containing inositol 5' phosphatase 2)** inhibitor, with an IC_{50} of 620 nM. AS1949490 activated glucose metabolism via up-regulation of GLUT1 gene in L6 myotubes.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Azadirachtin B

Cat. No.: HY-133108

Azadirachtin B is an limonoid isolated from seed kernels of Azadirachta indica. Azadirachtin B increases alkaline phosphatase (ALP) activity and stimulates osteoblast differentiation. Azadirachtin B is active against the **Epstein-Barr virus early antigen (EBV-EA)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BCI

((E)-BCI)

Cat. No.: HY-115502

BCI is an allosteric inhibitor of dual specificity phosphatase (**DUSP**). BCI specifically inhibits **DUSP6** and **DUSP1** with EC_{50}s of 13.3 and 8.0 μM in cells, respectively. BCI does not inhibit DUSP5.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

BCI hydrochloride

((E)-BCI hydrochloride)

Cat. No.: HY-115502A

BCI hydrochloride ((E)-BCI hydrochloride) is an allosteric inhibitor of dual specificity phosphatase (**DUSP**). BCI hydrochloride specifically inhibits **DUSP6** and **DUSP1** with EC_{50}s of 13.3 and 8.0 μM in cells, respectively. BCI hydrochloride does not inhibit DUSP5.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

BCI-215

Cat. No.: HY-121087

BCI-215 is a potent and tumor cell-selective **dual specificity MAPK phosphatase (DUSP-MKP)** inhibitor. BCI-215 has cytotoxicity for tumor cells but not normal cells.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Bis(maltolato)oxovanadium(IV)

(BMOV)

Cat. No.: HY-118567

Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-**PTP (protein tyrosine phosphatases)** inhibitor.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mg

BN82002

Cat. No.: HY-112776

BN82002 is a potent, selective and irreversible inhibitor of **CDC25 phosphatase** family. BN82002 inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC_{50} values of 2.4, 3.9, 6.3, 5.4, and 4.6 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BN82002 hydrochloride

Cat. No.: HY-112776A

BN82002 hydrochloride is a potent, selective and irreversible inhibitor of **CDC25 phosphatase** family. BN82002 hydrochloride inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC_{50} values of 2.4, 3.9, 6.3, 5.4, and 4.6 μM, respectively.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

bpV(phen)

Cat. No.: HY-136065

bpV(phen), a insulin-mimetic agent, is a potent **protein tyrosine phosphatase (PTP)** and **PTEN** inhibitor with IC_{50}s of 38 nM, 343 nM and 920 nM for **PTEN**, **PTP-β** and **PTP-1B**, respectively. bpV(phen) inhibits proliferation of the protozoan **parasite Leishmania** in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

bpV(phen) trihydrate

Cat. No.: HY-122818

bpV(phen) trihydrate, a insulin-mimetic agent, is a potent **protein tyrosine phosphatase (PTP)** and **PTEN** inhibitor with IC_{50}s of 38 nM, 343 nM and 920 nM for **PTEN**, **PTP-β** and **PTP-1B**, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BTdCPU

Cat. No.: HY-118266

BTdCPU is a potent **heme-regulated eIF2α kinase (HRI)** activator. BTdCPU promotes eIF2α **phosphorylation** and induced **apoptosis** in resistant cell.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BVT948

Cat. No.: HY-100625

BVT948 is a **protein tyrosine phosphatase** (**PTP**) inhibitor which can also inhibit several **cytochrome P450** (**P450**) isoforms and lysine methyltransferase **SETD8** (**KMT5A**).



Purity: 98.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

C2 Ceramide

(Ceramide 2)

Cat. No.: HY-101180

C2 Ceramide (Ceramide 2) is the main lipid of the stratum corneum and a **protein phosphatase 1 (PP1)** activator. C2 Ceramide activates **PP2A** and **ceramide-activated protein phosphatase (CAPP)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Calcineurin autoinhibitory peptide

Cat. No.: HY-P1247

Calcineurin autoinhibitory peptide is a selective inhibitor of **Ca^{2+}/calmodulin-dependent protein phosphatase (calcineurin)**, with an **IC_{50}** of ~10 μM. Calcineurin autoinhibitory peptide could protect neurons from excitatory neuronal death.

Purity: 99.71%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Calcineurin autoinhibitory peptide TFA

Cat. No.: HY-P1247A

Calcineurin autoinhibitory peptide TFA is a selective inhibitor of **Ca^{2+}/calmodulin-dependent protein phosphatase (calcineurin)**, with an **IC_{50}** of ~10 μM. Calcineurin autoinhibitory peptide TFA could protect neurons from excitatory neuronal death.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calcium glycerophosphate

Cat. No.: HY-B2203

Calcium glycerophosphate is an inhibitor of **intestinal alkaline phosphatase F3**. Calcium glycerophosphate is a source of calcium and phosphorus in total parenteral nutrition solutions.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

Calyculin A

((-)-Calyculin A)

Cat. No.: HY-18983

Calyculin A ((-)-Calyculin A) is a potent and cell-permeable protein phosphatase 1 (**PP1**) and protein phosphatase 2A (**PP2A**) inhibitor with **IC_{50}**s of 2 nM and 0.5-1 nM, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 100 μg (0.5 mM * 200 μL in DMSO)

Cassiaside B2

Cat. No.: HY-N8200

Cassiaside B2 is a protein tyrosine phosphatase 1B **(PTP1B)** and **human monoamine oxidase A (hMAO-A)** inhibitor. Cassiaside B2 possesses antiallergic and is a **5-HT2C** receptor agonist..



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

CCT007093

Cat. No.: HY-15880

CCT007093 is an effective **protein phosphatase 1D (PPM1D Wip1)** inhibitor. Wip1 inhibition can activate the mTORC1 pathway and enhance hepatocyte proliferation after hepatectomy.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

CDC25B-IN-1

Cat. No.: HY-126246

CDC25B-IN-1 (compound 4a) is a potent inhibitor of **cell division cycle 25B (CDC25B) phosphatase**, with a **K_i** of 8.5 μM. CDC25B-IN-1 potently inhibits cell proliferation and colony formation, causes an increase of the G2/M phase.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDC25B-IN-2

Cat. No.: HY-137175A

CDC25B-IN-2 is a potent **cdc25B** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Chrysophanol triglucoside

Cat. No.: HY-N7599

Chrysophanol triglucoside is an anthraquinone isolated from Cassia obtusifolia, inhibits **protein tyrosine phosphatases 1B (PTP1B)** and **α-glucosidase** with **IC_{50}**s of 80.17 and 197.06 μM, respectively. Chrysophanol triglucoside has the potential for diabetes research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

CPDA

Cat. No.: HY-18685

CPDA is a novel potent SH2 domain-containing inositol phosphatase 2 (SHIP2) inhibitor.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CPT-157633

Cat. No.: HY-111469

CPT-157633, a difluoro-phosphonomethyl phenylalanine derivative, and is a **PTP1B** inhibitor. CPT-157633 prevents binge drinking-induced glucose intolerance.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Cyanidin 3-arabinoside

Cat. No.: HY-N4143

Cyanidin 3-arabinoside is a selective and reversible **protein tyrosine phosphatase 1B (PTP1B)** inhibitor, with an IC_{50} of 8.91 μM. Cyanidin 3-arabinoside is potential for the research of type 2 diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Cyclosporin A

(Cyclosporine A; Ciclosporin A; CsA)

Cat. No.: HY-B0579

Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of **calcineurin** with an IC_{50} of 5 nM. Cyclosporin A also inhibits **CD11a/CD18** adhesion.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

cyt-PTPε Inhibitor-1

Cat. No.: HY-112800

cyt-PTPε Inhibitor-1 is a potent cytosolic protein tyrosine phosphatase epsilon (**cyt-PTPε**) inhibitor, binds to the catalytic domain of cyt-PTPε, blocks c-Src activation (dephosphorylation of c-Src), and exhibits anti-osteoclastic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cytostatin

Cat. No.: HY-113612

Cytostatin is a potent and selective inhibitor of PP_2A with promising antitumor activity. Cytostatin is also an inhibitor of cell adhesion to extracellular matrix and induces cell **apoptosis**. Cytostatin belongs to the fostriecin family of natural products.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

D-3

Cat. No.: HY-P2286

D-3, a phosphorpeptide, is an efficient, simple, and specific iPSC-eliminating agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D-erythro-Sphingosine (Erythrosphingosine; erythro-C18-Sphingosine; trans-4-Sphingenine)

Cat. No.: HY-101047

D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of **p32-kinase** with an EC_{50} of 8 μM, and inhibits **protein kinase C (PKC)**. D-erythro-Sphingosine (Erythrosphingosine) is also a **PP2A** activator.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

D-erythro-Sphingosine-d7 (Erythrosphingosine-d7; erythro-C18-Sphingosine-d7; trans-4-Sphingenine-d7)

Cat. No.: HY-101047S

D-erythro-Sphingosine-d7 (Erythrosphingosine-d7) is the deuterium labeled D-erythro-Sphingosine. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of **p32-kinase** with an EC_{50} of 8 μM, and inhibits **protein kinase C (PKC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg

Dibefurin

Cat. No.: HY-N10186

Dibefurin is a fungal metabolite that acts as an inhibitor of **calcineurin phosphatase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DIPQUO

Cat. No.: HY-128591

DIPQUO is an activator of the bone marker **alkaline phosphatase (ALP)**, with an EC_{50} of 6.27 μM in C2C12 cells. DIPQUO promotes mouse and human osteoblast differentiation via activation of p38 MAPK-β.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

DJ001

Cat. No.: HY-133146

DJ001 is a highly specific, selective and non-competitive **protein tyrosine phosphatase-σ (PTPσ)** inhibitor with an IC_{50} of 1.43 μM. DJ001 displays no inhibitory activity against other phosphatases, with only modest inhibitory activity against Protein Phosphatase 5.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DPM-1001

Cat. No.: HY-121515

DPM-1001 is a potent, specific, orally active and non-competitive inhibitor of **protein-tyrosine phosphatase (PTP1B)** with an IC_{50} of 100 nM. DPM-1001 is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 has anti-diabetic property.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DPM-1001 trihydrochloride

Cat. No.: HY-121515A

DPM-1001 trihydrochloride is a potent, specific, orally active and non-competitive inhibitor of **protein-tyrosine phosphatase (PTP1B)** with an IC_{50} of 100 nM. DPM-1001 trihydrochloride is an analog of the specific PTP1B inhibitor MSI-1436. DPM-1001 trihydrochloride has anti-diabetic property.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

DT-061

Cat. No.: HY-112929

DT-061 is an orally bioavailable activator of **protein phosphatase 2A (PP2A)** and could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ebselen

(SPI-1005; PZ-51; CCG-39161)

Cat. No.: HY-13750

Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent **voltage-dependent calcium channel (VDCC)** blocker. Ebselen potently inhibits M^{pro} (IC_{50}=0.67 μM) and **COVID-19** virus (EC_{50}=4.67 μM).Ebselen is an inhibitor of **HIV-1** capsid CTD dimerization.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Endothall

(Endothal)

Cat. No.: HY-113976A

Endothall (Endothal) is a protein phosphatase 2A (**PP2A**) inhibitor with IC_{50}s of 90 nM and 5 μM for PP2A and PP1, respectively. Endothall can be used as an herbicide. Endothall also is useful in cancer chemotherapy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enocyanin

Cat. No.: HY-114336

Enocyanin is an anthocyanin extracted from grapes. Enocyanin shows inhibitory effect on the leucine aminopeptidase, acid phosphatase, γ-glutamyl transpeptidase and esterase activity.

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mg(10 mg × mL in DMSO), 100 mg

Ertiprotafib

(PTP 112)

Cat. No.: HY-19383

Ertiprotafib is an inhibitor of **PTP1B, IkB kinase β (IKK-β)**, and a dual **PPARα and PPARβ** agonist, with an IC_{50} of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC_{50} of ~1 μM for PPARα/PPARβ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

F1063-0967

Cat. No.: HY-101510

F1063-0967 is a **Dual-specificity phosphatase 26 (DUSP26)** inhibitor with an IC_{50} of 11.62 μM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fenvalerate

Cat. No.: HY-B2006

Fenvalerate is a potent **protein phosphatase 2B (calcineurin)** inhibitor with an IC_{50} of 2-4 nM for PP2B-Aα. Fenvalerate is a pyrethroid ester insecticide and acaricide.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Fenvalerate-d5

Cat. No.: HY-B2006S

Fenvalerate-d5 is the deuterium labeled Fenvalerate. Fenvalerate is a potent **protein phosphatase 2B (calcineurin)** inhibitor with an IC_{50} of 2-4 nM for PP2B-Aα. Fenvalerate is a pyrethroid ester insecticide and acaricide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GDC-1971

Cat. No.: HY-144903

GDC-1971 (compound 199) is a **SHP2** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ginkgolic acid C17:1

Cat. No.: HY-N2116

Ginkgolic acid C17:1, extracted from Ginkgo biloba Leaves, suppresses constitutive and inducible STAT3 activation through induction of **PTEN** and **SHP-1** tyrosine phosphatase. Ginkgolic acid C17:1 has anticancer effects.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Glycerophosphate-d5 disodium pentahydrate

Cat. No.: HY-D0886S

Glycerophosphate-d5 disodium pentahydrate is the deuterium labeled β-Glycerophosphate disodium salt pentahydrate. β-Glycerophosphate disodium salt pentahydrate is a **phosphatase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNF362

Cat. No.: HY-126750

GNF362 is a selective, potent, and orally bioavailable inhibitor of **inositol trisphosphate 3' kinase B (Itpkb)** with an IC_{50} of 9 nM. GNF362 also inhibits Itpka and Itpkc with IC_{50} values of 20 nM and 19 nM, respectively.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GS-493

Cat. No.: HY-120159

GS-493 is a selective protein tyrosine phosphatase **SHP2** (PTPN11) inhibitor with an IC_{50} of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK 2830371

Cat. No.: HY-15832

GSK 2830371 is a highly selective **Wip1 phosphatase** inhibitor with IC_{50} of 6 nM.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

IACS-13909

Cat. No.: HY-137092

IACS-13909 is a selective, potent and orally active **SHP2** allosteric inhibitor with an IC_{50} of 15.7 nM and a K_d of 32 nM. IACS-13909 is more selective for **SHP2** than other phosphatases (including SHP1).



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

IACS-15414

Cat. No.: HY-132901

IACS-15414 is a potent and orally bioavailable **SHP2** inhibitor with an IC_{50} value of 122 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Icerguastat

(Sephin1; IFB-088)

Cat. No.: HY-111022

Icerguastat (Sephin1), a derivative of Guanabenz lacking the α2-adrenergic activity, is a selective inhibitor of the phosphatase regulatory subunit **PPP1R15A (R15A)**. Icerguastat inhibits eIF2α dephosphorylation, thereby prolonging the protective response. Anti-prion effect.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Isotanshinone IIA

Cat. No.: HY-N6650

Isotanshinone IIA, an abietane-type diterpene metabolite, could non-competitively inhibit Protein Tyrosine Phosphatase 1B (**PTP1B**) activity with an IC_{50} 0f 11.4 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

JTT 551

Cat. No.: HY-19779

JTT 551 is selective a protein tyrosine phosphatase 1B (**PTP1B**) inhibitor, with K_is of 0.22 μM and 9.3 μM for PTP1B and TCPTP (T-cell protein tyrosine phosphatase), respectively; JTT 551 can be used in the research of type 2 diabetes mellitus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KLH45

Cat. No.: HY-103060

KLH45 is a potent and selective **DDHD2** inhibitor, with an IC_{50} of 1.3 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

KY-226

Cat. No.: HY-120327

KY-226 is a potent, selective, orally active and allosteric **protein tyrosine phosphatase 1B (PTP1B)** inhibitor with an IC_{50} of 0.25 μM, and without PPARγ agonist activity.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-690330

Cat. No.: HY-101075

L-690330 is a competitive inhibitor of **inositol monophosphatase (IMPase)** with K_is of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively. L-690330 exhibits 10-fold more sensitive than mouse and rat IMPase.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

L-690330 hydrate

Cat. No.: HY-101075A

L-690330 hydrate is a competitive inhibitor of **inositol monophosphatase (IMPase)** with K_is of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

L-690488

Cat. No.: HY-101076

L-690488 is a prodrug of L-690330 and is a selective **inositol monophosphatase (IMPase)** inhibitor. L-690488 has more effective cell penetration than L-690330.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

L-Ascorbic acid 2-phosphate

(2-Phospho-L-ascorbic acid)

Cat. No.: HY-103701

L-ascorbic acid 2-phosphate (2-Phospho-L-ascorbic acid) is a long-acting ;**vitamin C derivative** that can stimulate **collagen formation** and expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Ascorbic acid 2-phosphate magnesium

(2-Phospho-L-ascorbic acid magnesium)

Cat. No.: HY-103701A

L-Ascorbic acid 2-phosphate magnesium (2-Phospho-L-ascorbic acid magnesium) is a long-a cting **vitamin C derivative**&n bsp;that can stimulate **collagen formation** and expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Ascorbic acid 2-phosphate trisodium

(2-Phospho-L-ascorbic acid trisodium)

Cat. No.: HY-107837

L-Ascorbic acid 2-phosphate trisodium (2-Phospho-L-ascorbic acid trisodium) is a long-acting **vitamin C derivative** that can stimulate **collagen formation** and expression.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Licoflavone A

Cat. No.: HY-N4185

Licoflavone A is a flavonoid isolated from the roots of Glycyrrhiza uralensis, inhibits protein tyrosine phosphatase-1B (**PTP1B**), with an IC_{50} of 54.5 μM.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

LMPTP inhibitor 1

Cat. No.: HY-111489

LMPTP inhibitor 1 is a selective inhibitor of low molecular weight protein tyrosine phosphatase (**LMPTP**), with an IC_{50} of 0.8 μM LMPTP-A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LMPTP inhibitor 1 dihydrochloride

Cat. No.: HY-111489B

LMPTP INHIBITOR 1 (dihydrochloride) is a selective inhibitor of low molecular weight protein tyrosine phosphatase (**LMPTP**), with an IC_{50} of 0.8 μM LMPTP-A.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LMPTP inhibitor 1 hydrochloride

Cat. No.: HY-111489A

LMPTP inhibitor 1 hydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase (**LMPTP**), with an IC_{50} of 0.8 μM LMPTP-A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LTV-1

Cat. No.: HY-18667

LTV-1 is a potent lymphoid tyrosine phosphatase (**LYP**) inhibitor in T cells with an IC_{50} of 508 nM. LTV-1 has the potential for autoimmunity treatment.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LYP-IN-1

Cat. No.: HY-108944

LYP-IN-1 is a potent, selective and specific **LYP** inhibitor with a K_i and an IC_{50} of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC_{50}=5 μM) and SHP2 (IC_{50}=2.5 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Managlinat dialanetil

(MB06322; CS-917)

Cat. No.: HY-14955

Managlinat dialanetil (MB06322) is an orally bioavailable inhibitor of **fructose 1,6-bisphosphatase (FBPase)** for the treatment of type 2 diabetes .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MB05032

Cat. No.: HY-16307

MB05032 is a special and efficacious gluconeogenesis inhibitor targeted the AMP binding site of **fructose 1,6-bisphosphatase (FBPase)** with an IC_{50} value of 16 nM.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Microcystin-LA

Cat. No.: HY-P0219

Microcystin LA, a natural toxin, exerts its cytotoxic exects by inhibiting the serine-threonine protein phosphatases **PP1** and **PP2A** with IC_{50}s of 0.3 and 0.3 nM, respectively.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 100 μg

MLS-0437605

Cat. No.: HY-123846

MLS-0437605 is a selective **dual-specificity phosphatase 3 (DUSP3)** inhibitor with an IC_{50} of 3.7 μM. MLS-0437605 is more selective for DUSP3 than DUSP22 and other protein tyrosine phosphatases (PTPs).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MLS000544460

Cat. No.: HY-133511

MLS000544460 is a highly selective and reversible **Eya2 phosphatase** inhibitor with a K_d of 2.0 μM and an IC_{50} of 4 μM. MLS000544460 inhibit Eya2 phosphatase mediated cell migration and has anti-cancer activity.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Momordicoside A

Cat. No.: HY-N2111

Momordicoside A is isolated from Momordica charantia L. Momordicoside A has the inhibitory effect on **protein tyrosine phosphatase (PTP1B)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MP07-66

Cat. No.: HY-123794

MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to **PP2A** reactivation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MSI-1436

(Trodusquemine; Aminosterol-1436)

Cat. No.: HY-12219

MSI-1436 is a selective, non-competitive inhibitor of the enzyme **protein-tyrosine phosphatase 1B (PTP1B)**, with an IC_{50} of appr 1 μM, 200-fold preference over TCPTP (IC_{50}, 224 μM).



Purity: ≥95.0%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 50 mg

MSI-1436 lactate

(Trodusquemine lactate; Aminosterol-1436 lactate)

Cat. No.: HY-12219A

MSI-1436 lactate is a selective, non-competitive inhibitor of the enzyme **protein-tyrosine phosphatase 1B (PTP1B)**, with an IC_{50} of 1 μM, 200-fold preference over TCPTP (IC_{50} of 224 μM).



Purity: ≥95.0%
Clinical Data: Phase 1
Size: 1 mg, 5 mg, 10 mg, 50 mg

MY10

Cat. No.: HY-123856

MY10 is a potent and orally active **receptor protein tyrosine phosphatase (RPTPβ/ζ)** inhibitor. MY10 attenuates binge-like ethanol consumption and ethanol reward.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MY33-3

Cat. No.: HY-123966

MY33-3 is a potent and selective inhibitor of **receptor protein tyrosine phosphatase (RPTP)β/ζ**, with an IC_{50} of ~0.1 μM. MY33-3 also inhibits **PTP-1B** (IC_{50} ~0.7 μM). MY33-3 can reduce ethanol consumption and alleviate Sevoflurane-induced neuroinflammation and cognitive dysfunction.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naphthol AS-BR

Cat. No.: HY-121932

Naphthol AS-BR is a substrate for the histochemical demonstration of acid and alkaline phosphatase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NAZ2329

Cat. No.: HY-103693

NAZ2329, the first cell-permeable inhibitor of R5 subfamily of receptor-type protein tyrosine phosphatases (RPTPs), allosterically and preferentially inhibits **PTPRZ** (IC_{50}=7.5 μM for hPTPRZ1) and **PTPRG** (IC_{50}=4.8 μM for hPTPRG) over other PTPs.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCGC00249987

Cat. No.: HY-133512

NCGC00249987 is a highly selective and allosteric Tyr phosphatase activity of **Eya2** inhibitor with IC_{50}s of 3 μM and 6.9 μM for Eya2 ED and MBP-Eya2 FL. NCGC00249987 specifically targets migration, invadopodia formation, and invasion of lung cancer cells.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCGC00378430

Cat. No.: HY-138657

NCGC00378430 is a potent **SIX1/EYA2** interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT).



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC 663284

(DA-3003-1)

Cat. No.: HY-100034

NSC 663284 (DA-3003-1) is a potent, cell-permeable, and irreversible **Cdc25 dual specificity phosphatase** inhibitor, has an IC_{50} for Cdc25B2 of 0.21 μM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC 95397

Cat. No.: HY-108543

NSC 95397 is a potent, selective **Cdc25** dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC_{50}=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)).



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC-87877

Cat. No.: HY-18756

NSC-87877 is a potent inhibitor of **Shp2** and **Shp1** protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC_{50} values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits **dual-specificity phosphatase 26 (DUSP26)**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC-87877 disodium

Cat. No.: HY-18756A

NSC-87877 disodium is a potent inhibitor of **Shp2** and **Shp1** protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC_{50} values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits **dual-specificity phosphatase 26 (DUSP26)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Okadaic acid

Cat. No.: HY-N6785

Okadaic acid, a marine toxin, is an inhibitor of protein phosphatases (PP).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 μg (124.2 μM * 250 μL in Ethanol)

Okadaic acid ammonium salt

Cat. No.: HY-115760

Okadaic acid ammonium salt, a marine toxin, is an inhibitor of **protein phosphatases (PP)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pentamidine

(MP-601205)

Cat. No.: HY-B0537

Pentamidine (MP-601205) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine inhibits parasite **Leishmania infantum** with an IC_{50} of 2.5 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pentamidine dihydrochloride

(MP-601205 dihydrochloride)

Cat. No.: HY-B0537A

Pentamidine dihydrochloride (MP-601205 dihydrochloride) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine dihydrochloride inhibits parasite **Leishmania infantum** with an IC_{50} of 2.5 μM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pentamidine isethionate

(MP-601205 isethionate)

Cat. No.: HY-B0537B

Pentamidine isethionate (MP-601205 isethionate) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine isethionate inhibits parasite **Leishmania infantum** with an IC_{50} of 2.5 μM.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Pentamidine-d4 dihydrochloride

(MP-601205-d4 dihydrochloride) Cat. No.: HY-B0537AS

Pentamidine-d4 (MP-601205-d4) dihydrochloride is the deuterium labeled Pentamidine dihydrochloride. Pentamidine dihydrochloride (MP-601205 dihydrochloride) is an antimicrobial agent and interferes with DNA biosynthetics.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PGAM1-IN-1

Cat. No.: HY-128681

PGAM1-IN-1 is a **phosphoglycerate mutase 1** (**PGAM1**) inhibitor with an **IC_{50}** of 6.4 μM.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PGAM1-IN-2

Cat. No.: HY-128682

PGAM1-IN-2 is a **phosphoglycerate mutase 1** (**PGAM1**) inhibitor with an **IC_{50}** of 2.1 μM.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PGMI-004A

Cat. No.: HY-101143

PGMI-004A is a potent **phosphoglycerate mutase 1** (**PGAM1**) inhibitor with an **IC_{50}** of 13.1 μM.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Phostriecin

Cat. No.: HY-N10223

Phostriecin is an antitumor antibiotic produced by Streptomyces pulveraceus. Phostriecin is a strong inhibitor of type 2A (**PP2A**) and a weak inhibitor of type 1 (**PP1**) serine/threonine protein phosphatases with **IC_{50}**s of 3.2 nM and 131 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHPS1

Cat. No.: HY-112368

PHPS1 is a potent and selective **Shp2** inhibitor with **K_i**s of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHPS1 sodium

Cat. No.: HY-125108

PHPS1 sodium is a potent and selective **Shp2** inhibitor with **K_i**s of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

PRL-3 Inhibitor I

Cat. No.: HY-112476

PRL-3 Inhibitor I is a potent **PRL-3** inhibitor with an **IC_{50}** of 0.9 μM. PRL-3 Inhibitor I shows a reduced invasion in cell-based assay.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Prunin

(Naringenin 7-0-glucoside) Cat. No.: HY-N1549

Prunin is a potent inhibitor of human enterovirus A71 (HEVA71). Prunin shows strong inhibitory activity against protein tyrosine phosphatase 1B (PTP1B), with an IC_{50} of 5.5 μM.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PTP inhibitor 1

Cat. No.: HY-W013478

PTP inhibitor 1 is a **protein tyrosine phosphatase (PTP)** inhibitor, with anti-angiogenic effect.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

PTP1B-IN-1

(PTP1B inhibitor)

Cat. No.: HY-10704

PTP1B-IN-1 is a potent protein tyrosine phosphatase-1B (PTP1B) inhibitor with IC50 of 1.6 mM; 1,2,5-thiadiazolidin-3-one-1,1-dioxide scaffold for derivatives synthesis.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PTP1B-IN-13

Cat. No.: HY-139640

PTP1B-IN-13 is a selective **PTP1B** inhibitor targeting the allosteric site with an IC_{50} value of 1.59 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PTP1B-IN-14

Cat. No.: HY-139641

PTP1B-IN-14 is a selective **PTP1B** inhibitor (IC_{50} = 0.72 μM) targeting the allosteric site.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PTP1B-IN-15

Cat. No.: HY-108196

PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (**PTP1B**). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PTP1B-IN-2

Cat. No.: HY-100462

PTP1B-IN-2 is a potent protein tyrosine phosphatase 1B (**PTP1B**) inhibitor with an IC_{50} of 50 nM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PTP1B-IN-3

Cat. No.: HY-15133

PTP1B-IN-3 is a potent and orally active **PTP1B** inhibitor with IC_{50}s of 120 nM for both **PTP1B** and TCPTP. PTP1B-IN-3 has antidiabetic and anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PTP1B-IN-3 diammonium

Cat. No.: HY-15133A

PTP1B-IN-3 diammonium is a potent and orally active **PTP1B** inhibitor with IC_{50}s of 120 nM for both **PTP1B** and TCPTP. PTP1B-IN-3 diammonium has antidiabetic and anticancer effects.



Purity: 95.38%
Clinical Data: No Development Reported
Size: 1 mg

PTP1B-IN-4

Cat. No.: HY-15756

PTP1B-IN-4 is a non-competitive allosteric inhibitor of the protein tyrosine phosphatase **PTP1B**, with an IC_{50} of 8 μM. PTP1B-IN-4 is potentail for the research of obesity and diabetes.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PTPN22-IN-1

Cat. No.: HY-139693

PTPN22-IN-1 is a potent **PTPN22** inhibitor (IC_{50}=1.4 μM; K_i=0.50 μM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses. From WO2021007491A1 compound L-1.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Raphin1

Cat. No.: HY-123960

Raphin1 is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B **(R15B)**. Raphin1 binds strongly to the R15B-PP1c holophosphatase (K_d=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Raphin1 acetate

Cat. No.: HY-123960A

Raphin1 acetate is an orally bioavailable, selective inhibitor of the regulatory phosphatase **PPP1R15B (R15B)**. Raphin1 acetate binds strongly to the R15B-PP1c holophosphatase (K_d=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Razuprotafib

(AKB-9778)

Cat. No.: HY-109041

Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of **VE-PTP (vascular endothelial protein tyrosine phosphatase)** with an $IC_{50}$of 17 pM.



Purity: 99.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Rbin-1

(Ribozinoindole-1)

Cat. No.: HY-100816

Rbin-1 is a potent, reversible, and specific chemical inhibitor of eukaryotic ribosome biogenesis. Rbin-1 inhibits the **ATPase** with GI_{50} of 136 nM. Rbin-1 is a potent and selective chemical inhibitor of Midasin (Mdn1).



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rhein-8-glucoside calcium

Cat. No.: HY-N0312

Rhein-8-glucoside calcium, an anthraquinone compound, is isolated from the EtOH extract of the roots of Saussurea lappa. Rhein-8-glucoside calcium is an **hPTP1B** inhibitor, with an IC_{50} of 11.5 μM. Rhein-8-glucoside calcium has antibacterial effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Rilapladib

(SB 659032)

Cat. No.: HY-102004

Rilapladib (SB 659032) is a selective **Lp-PLA$_2$** (lipoprotein-associated phospholipase A_2) inhibitor with an IC_{50} of 230 pM. Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist.



Purity: 99.93%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RMC-3943

Cat. No.: HY-141524

RMC-3943 is an allosteric **SHP2** inhibitor (inhibition of full-length SHP2 in biochemical assay, IC_{50} = 2.19 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RMC-4550

Cat. No.: HY-116009

RMC-4550 is a potent, selective and allosteric inhibitor of **SHP2**, with an IC_{50} of 0.583 nM.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RMC-4630

(SHP2-IN-7)

Cat. No.: HY-141523

RMC-4630 (SHP2-IN-7) is an **SHP2** inhibitor extracted from patent WO2018013597.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ro 90-7501

Cat. No.: HY-103241

Ro 90-7501 is an **amyloid β_{42} ($A\beta_{42}$) fibril assembly** inhibitor that reduces **$A\beta_{42}$**-induced cytotoxicity (EC_{50} of 2 μM). Ro 90-7501 inhibits **ATM** phosphorylation and DNA repair.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rosiptor

(AQX-1125)

Cat. No.: HY-109011

Rosiptor (AQX-1125) is a selective and orally active phosphatase **SHIP1** activator with anti-inflammatory effects. Rosiptor (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rubratoxin A

Cat. No.: HY-126730

Rubratoxin A is a natural mycotoxin and competitive inhibitor of **protein phosphatase 2A** (PP2A) with an IC_{50} of 170 nM. Rubratoxin A causes suppression of tumor metastasis and reduction of primary tumor volume in mouse xenografts.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sal003

Cat. No.: HY-15969

Sal003 is a potent, specific and cell-permeable inhibitor of the **eukaryotic translation initiation factor 2α (eIF2α) phosphatase**. Sal003 is a derivative of salubrinal.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Salubrinal

Cat. No.: HY-15486

Salubrinal is a cell-permeable and selective inhibitor of **eIF2α dephosphorylation**. Salubrinal acts as a dual-specificity phosphatase 2 (**Dusp2**) inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SBI-425

Cat. No.: HY-124756

SBI-425 is a potent, selective and oral bioavailable **tissue-nonspecific alkaline phosphatase (TNAP)** inhibitor.



Purity: 99.40%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC-43

Cat. No.: HY-136657

SC-43, a Sorafenib derivative, is a potent and orally active **SHP-1 (PTPN6)** agonist. SC-43 inhibits the phosphorylation of **STAT3** and induces cell **apoptosis**. SC-43 has anti-fibrotic and anticancer effects.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SF1670

Cat. No.: HY-15842

SF1670 is a potent and specific phosphatase and tensin homolog deleted on chromosome 10 (**PTEN**) inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SHIP2-IN-1

Cat. No.: HY-112700

SHIP2-IN-1 is a potent **SHIP2** inhibitor, inhibits SHIP2 activity, with an IC_{50} of 2 μM. SHIP2-IN-1 blocks GSK3β activation by phosphorylation at the Ser9 residue. SHIP2-IN-1 is used in the research of Alzheimer's disease.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SHP099

Cat. No.: HY-100388

SHP099 is a potent, selective, orally available **SHP2** inhibitor with an IC_{50} of 70 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SHP099 hydrochloride

Cat. No.: HY-100388A

SHP099 hydrochloride is a potent, selective and orally available **SHP2** inhibitor with an IC_{50} of 70 nM.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SHP2 inhibitor LY6 (LY6)

Cat. No.: HY-125257

SHP2 inhibitor LY6 (LY6) is potent and selective inhibitor of **SHP2**, with an IC_{50} of 9.8 μM. SHP2 inhibitor LY6 can inhibits SHP2-mediated cell signaling and proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHP2 protein degrader-1

Cat. No.: HY-145159

SHP2 protein degrader-1 is a potent allosteric inhibitor of **SHP2**. SHP2 protein degrader-1 induces SHP2 degradation and cell **apoptosis**. SHP2 protein degrader-1 has the potential for researching SHP2 related diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHP2-D26

Cat. No.: HY-145162

SHP2-D26 is a first, potent and effective **SHP2** degrader. SHP2-D26 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins. SHP2-D26 is also neddylation- and proteasome-dependent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHP2-IN-1

Cat. No.: HY-114460

SHP2-IN-1 (compound 13) is an allergic inhibitor of **SHP2 (PTPN11)**, with an IC_{50} of 3 nM.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHP2-IN-6

Cat. No.: HY-131132

SHP2-IN-6 is a potent **SHP2** inhibitor, extracted from patent WO2017211303A1, compound 7, has an IC_{50} of 25.8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHP2-IN-6 hydrochloride

Cat. No.: HY-131132A

SHP2-IN-6 hydrochloride is a potent **SHP2** inhibitor with an IC_{50} of 25.8 nM. SHP2-IN-6 hydrochloride is extracted from patent WO2017211303A1, compound 7.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SHP2-IN-8

Cat. No.: HY-144396

SHP2-IN-8 is a highly potent, selective, and cellularly active allosteric **SHP2** inhibitor with IC_{50} value of 23 nM and K_i of 22 nM. SHP2-IN-8 is reversible and noncompetitive. SHP2-IN-8 causes a significant thermal shift with the ΔTm of 7.01 .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHP2-IN-9

Cat. No.: HY-115925

SHP2-IN-9 is a specific **SHP2** inhibitor (IC_{50} =1.174 μM) with enhanced blood–brain barrier penetration. SHP2-IN-9 shows 85-fold more selective for SHP2 than SHP1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHP389

Cat. No.: HY-114453

SHP389 is an allosteric **SHP2** inhibitor, with an IC_{50} of 36 nM for both SHP2 and p-ERK.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SHP394

Cat. No.: HY-114397

SHP394 is an orally active, selective and allosteric inhibitor of **SHP2**, with an IC_{50} of 23 nM.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

SHP504

Cat. No.: HY-125259

SHP504 is a **SHP2 phosphatase** inhibitor, with an IC_{50} of 21 μM for $SHP2^{1-525}$.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

SHP836

Cat. No.: HY-121879

SHP836 is a **SHP2** allosteric inhibitor, with an IC_{50} of 12 μM for the full length SHP2.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Silydianin

Cat. No.: HY-N0646

Silydianin is an active constituent of Silybium marianum, with exhibit anti-collagenase, antitumor and anti-elastase activities. Silydianin is a natural **protein tyrosine phosphatase 1B (PTP1B)** with an IC_{50} of 17.38μM.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

SMAP-2

(DT-1154)

Cat. No.: HY-120272

SMAP-2 (DT-1154) is an orally active **protein phosphatase 2A (PP2A)** activator, with anti-cancer activity.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Sodium metatungstate

(Sodium polyoxotungstate; POM-1)

Cat. No.: HY-103259

Sodium metatungstate (Sodium polyoxotungstate) is a potent **ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase)** inhibitor, with K_i values of 2.58 μM, 3.26 μM, and 28.8 μM for NTPDase 1 (CD39), NTPDase 3 and NTPDase 2 respectively.

$3Na_2WO_4.9WO_3$

Purity: ≥93.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg

Sodium orthovanadate

Cat. No.: HY-D0852

Sodium orthovanadate is an inhibitor of protein tyrosine phosphatases, alkaline phosphatases and a number of ATPases, most likely acting as a phosphate analogue.

Na_3VO_4

Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

Sodium stibogluconate

(Stibogluconate trisodium nonahydrate)

Cat. No.: HY-100595

Sodium stibogluconate (Stibogluconate trisodium nonahydrate) is a potent inhibitor of **protein tyrosine phosphatase**. Sodium stibogluconate inhibits 99% of SHP-1, SHP-2 and PTP1B activity at 10, 100, 100 μg/mL, respectively.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg, 1 g

SPI-112

Cat. No.: HY-101964

SPI-112 is a potent, selective and competitive **SHP2 (PTPN11)** inhibitor with IC_{50}s of 1 μM, 18.3 μM and 14.5 μM for **SHP2**, protein tyrosine phosphatase (PTP) and PTP1B, respectively.



Purity: 97.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Suramin

Cat. No.: HY-B0879

Suramin is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin is a potent inhibitor of **sirtuins**: SirT1 (IC_{50}=297 nM), SirT2 (IC_{50}=1.15 μM), and SirT5 (IC_{50}=22 μM).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Suramin sodium salt

(Suramin hexasodium salt)

Cat. No.: HY-B0879A

Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin sodium salt is a potent inhibitor of **sirtuins**: SirT1 (IC_{50}=297 nM), SirT2 (IC_{50}=1.15 μM), and SirT5 (IC_{50}=22 μM).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Tacrolimus

(FK506; Fujimycin; FR900506)

Cat. No.: HY-13756

Tacrolimus (FK506), a macrocyclic lactone, binds to **FK506 binding protein (FKBP)** to form a complex. Tacrolimus inhibits **calcineurin phosphatase**, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tacrolimus monohydrate (FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate)

Cat. No.: HY-13756A

Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to **FK506 binding protein (FKBP)** to form a complex and inhibits **calcineurin phosphatase**, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tacrolimus-13C,d2

(FK506-13C,d2; Fujimycin-13C,d2; FR900506-13C,d2)

Cat. No.: HY-13756S

Tacrolimus-13C,D2 (FK506-13C,D2) is a 13C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to **FK506 binding protein (FKBP)** to form a complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Tartaric acid disodium dihydrate (Sodium tartrate dibasic dihydrate; Sodium tartrate dihydrate)

Cat. No.: HY-D0850

Tartaric acid disodium dihydrate is a Acid phosphatase inhibitor, is a sodium salt used in buffers for molecular biology and cell culture applications. Increases the rate of colchicine binding to tubulin1.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

Tautomycetin

Cat. No.: HY-108542

Tautomycetin is a potent and specifical **PP1** inhibitor with the potential **apoptosis**-inducing activity. Tautomycetin inhibits purified PP1 and PP2A enzymes with IC_{50}s of 1.6 nM and 62 nM, respectively.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 μg

Tautomycin

Cat. No.: HY-12728

Tautomycin, an antifungal antibiotic isolated from the bacterium Streptomyces verticillatus, is a potent and specific inhibitor of **protein phosphatases 1 and 2A** and induces contraction of smooth muscle under Ca^{2+}-free conditions, with K_{iapp} values of 0.16 nM and 0.4 nM for PP1...



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 25 μg

TCS 401

Cat. No.: HY-12312

TCS 401 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

TD52

Cat. No.: HY-135699

TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of **protein phosphatase 2A (CIP2A)** inhibitor. TD52 mediates the **apoptotic** effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tetramisole hydrochloride ((±)-Tetramisole hydrochloride; DL-Tetramisole hydrochloride; R-829)

Cat. No.: HY-B1194

Tetramisole hydrochloride is an inhibitor of alkaline phosphatases, is a high purity antiparasitic.



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 2 g

Tetramisole-d5 hydrochloride ((±)-Tetramisole-d5 hydrochloride; DL-Tetramisole-d5 hydrochloride; ...)

Cat. No.: HY-B1194S

Tetramisole-d5 ((±)-Tetramisole-d5) hydrochloride is the deuterium labeled Tetramisole hydrochloride. Tetramisole hydrochloride is an inhibitor of alkaline phosphatases, is a high purity antiparasitic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Thienopyridone

Cat. No.: HY-128153

Thienopyridone is a potent and selective **phosphatase of regenerating liver (PRL) phosphatase** inhibitor with IC_{50}s of 173 nM, 277 nM and 128 nM for **PRL-1**, **PRL-2**, and **PRL-3**, respectively. Thienopyridone shows minimal effects on other phosphatases.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

TNO155

Cat. No.: HY-136173

TNO155 is a potent selective and orally active allosteric inhibitor of wild-type **SHP2** (IC_{50}=0.011 μM). TNO155 has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.</br>.



Purity: 99.43%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TPI-1

Cat. No.: HY-100463

TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a **SHP-1** inhibitor; inhibits recombinant SHP-1 with an IC_{50} of 40 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TRC-766

Cat. No.: HY-131443

TRC-766 is a negative control of RTC-5 (TRC-382). TRC-766 binds protein phosphatase 2A (PP2A) and does not activate the phosphatase.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Trichomide A

Cat. No.: HY-P3410

Trichomide A is a potent activator of **SHP2**. Trichomide A is a natural cyclodepsipeptide. Trichomide A displays immunosuppressive activity against activated T lymphocyte–mediated immune responses in Con A-activated T cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trimyristin

Cat. No.: HY-N2511

Trimyristin, an active molluscicidal component of Myristica fragrans Houtt, significantly inhibits **acetylcholinesterase** (**AChE**), **acid** and **alkaline phosphatase** (**ACP/ALP**) activities in the nervous tissue of Lymnaea acuminata.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Trimyristin--d15

Cat. No.: HY-N2511S

Trimyristin--d15 is the deuterium labeled Trimyristin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin 8

Cat. No.: HY-W174279

Tyrphostin 8 is a **tyrosine kinase**, with an IC_{50} of 560 μM for **EGFR kinase**. Tyrphostin 8 is also a **GTPase** inhibitor. Tyrphostin 8 can inhibit the protein **serine/threonine phosphatase calcineurin** (IC_{50}=21 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Uralenol

Cat. No.: HY-N9326

Uralenol is a natural **PTP1B** inhibitor (IC_{50}=21. 5 μM) from Broussonetia papyrifera. PTP1B have been shown to play a major role in the dephosphorylation of the insulin receptor in many cellular and biochemical studies.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Voclosporin

(ISAtx-247)

Cat. No.: HY-106638

Voclosporin (ISAtx-247) is a **calcineurin (PP2B)** (CN) inhibitor.



Purity: 98.04%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ZLDI-8

Cat. No.: HY-123931

ZLDI-8 is a **Notch** activating/cleaving enzyme **ADAM-17** inhibitor and inhibits the cleavage of **Notch** protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

[pTyr5] EGFR (988-993)

Cat. No.: HY-P1799

[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[pTyr5] EGFR (988-993) (TFA)

Cat. No.: HY-P1799A

[pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

β-Glycerophosphate disodium salt hydrate

Cat. No.: HY-126304

β-Glycerophosphate disodium salt hydrate, an endogenous metabolite, is a **phosphatase** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 mg

β-Glycerophosphate disodium salt pentahydrate

Cat. No.: HY-D0886

β-Glycerophosphate disodium salt pentahydrate is a **phosphatase** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 mg, 1 g, 5 g